Cost-Effectiveness of Modifying Cardiovascular Disease Risk Factors in Qatar Using the Productivity-Adjusted Life Years (PALY) Metric
Author(s)
Dina Abushanab, PhD1, Rouaa Elhani, BPharm2, Mohamed3, Anas Hamad, MSc, PhD4, Manal Zidan, PharmD5, Daoud Al-Badriyeh, PhD6.
1Pharmacy, Hamad Medical Corporation, Doha, Qatar, 2Qatar University, Doha, Qatar, 3Qatar, 4Hamad Medical Corporation, Doha, Qatar, 5Primary healthcare corporation, Doha, Qatar, 6College of Pharmacy, Qatar University, Doha, Qatar.
1Pharmacy, Hamad Medical Corporation, Doha, Qatar, 2Qatar University, Doha, Qatar, 3Qatar, 4Hamad Medical Corporation, Doha, Qatar, 5Primary healthcare corporation, Doha, Qatar, 6College of Pharmacy, Qatar University, Doha, Qatar.
OBJECTIVES: This study aimed to evaluate the cost-effectiveness of four population-level interventions for controlling cardiovascular disease (CVD) risk factors among working-age adults with type 2 diabetes (T2D) in Qatar using the Productivity Adjusted Life Year (PALY) framework
METHODS: We adapted an existing Markov dynamic PALY-based model to quantify productivity gains and costs associated with four interventions ιν πεοπλε λοϖινγ ιν Θαταρ ωιτη Τ2Δ, αγεδ 40[[Unsupported Character - Symbol Font –]]65 ψεαρσ: There four interventions were (1) lifestyle modification, (2) systolic blood pressure (SBP) reduction, (3) smoking cessation, and (4) LDL-C reduction. The model estimated PALYs over a 10-year horizon (ϕρομ 2024 το 2033), stratified by gender and prevention type. The model Intervention costs were sourced from local Qatari healthcare data. Incremental cost-effectiveness ratios (ICERs) were calculated, and sensitivity analysis was performed to assess robustness of models. The study was done from a societal perspective.
RESULTS: All four intervention were cost-effective. Cumulative PALY gains ranged from 166,282 (LDL-C reduction) to 192,479 (lifestyle modification) over 10 years. The corresponding discounted ICERs were: QAR 202,886 for lifestyle modification, QAR 192,083 for SBP reduction, QAR 191,020 for smoking cessation, and QAR 228,759 for LDL-C reduction. Among these, smoking cessation achieved the lowest cumulative discounted ICER, indicating the least spending per additional PALY, while LDL-C reduction was the least efficient with the highest cost per additional PALY. Gender-stratified analyses revealed further variation in productivity gains and cost-effectiveness across prevention types
CONCLUSIONS: This is the first PALY-based cost-effectiveness study. Our findings provide actionable evidence for prioritizing high-value CVD prevention strategies, highlighting the importance of targeting SBP and lifestyle risk factors to maximize productivity and economic returns in Qatar.
METHODS: We adapted an existing Markov dynamic PALY-based model to quantify productivity gains and costs associated with four interventions ιν πεοπλε λοϖινγ ιν Θαταρ ωιτη Τ2Δ, αγεδ 40[[Unsupported Character - Symbol Font –]]65 ψεαρσ: There four interventions were (1) lifestyle modification, (2) systolic blood pressure (SBP) reduction, (3) smoking cessation, and (4) LDL-C reduction. The model estimated PALYs over a 10-year horizon (ϕρομ 2024 το 2033), stratified by gender and prevention type. The model Intervention costs were sourced from local Qatari healthcare data. Incremental cost-effectiveness ratios (ICERs) were calculated, and sensitivity analysis was performed to assess robustness of models. The study was done from a societal perspective.
RESULTS: All four intervention were cost-effective. Cumulative PALY gains ranged from 166,282 (LDL-C reduction) to 192,479 (lifestyle modification) over 10 years. The corresponding discounted ICERs were: QAR 202,886 for lifestyle modification, QAR 192,083 for SBP reduction, QAR 191,020 for smoking cessation, and QAR 228,759 for LDL-C reduction. Among these, smoking cessation achieved the lowest cumulative discounted ICER, indicating the least spending per additional PALY, while LDL-C reduction was the least efficient with the highest cost per additional PALY. Gender-stratified analyses revealed further variation in productivity gains and cost-effectiveness across prevention types
CONCLUSIONS: This is the first PALY-based cost-effectiveness study. Our findings provide actionable evidence for prioritizing high-value CVD prevention strategies, highlighting the importance of targeting SBP and lifestyle risk factors to maximize productivity and economic returns in Qatar.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE262
Topic
Economic Evaluation, Epidemiology & Public Health, Health Policy & Regulatory
Disease
Cardiovascular Disorders (including MI, Stroke, Circulatory), Diabetes/Endocrine/Metabolic Disorders (including obesity)